Pulmozyme market report sees growth on respiratory demand and transplant care

The Business Research Company says the Pulmozyme market is set for continued growth, driven by rising respiratory disease cases, more genetic screening, and expanding specialized respiratory care. North America held the largest share in 2025, while Asia-Pacific is expected to grow the fastest through the forecast period.

Why it matters: - Pulmozyme demand is tied to the rising burden of chronic respiratory disease, including asthma, COPD, and pneumonia. - The market outlook also reflects broader use in specialist care and post-transplant treatment, where mucus clearance can affect infection risk and lung function.

What happened: - The Business Research Company released a Pulmozyme market analysis report on November 10, 2026. - The report says North America held the largest Pulmozyme market share in 2025. - The report projects Asia-Pacific as the fastest-growing regional market over the forecast period. - The company made a free sample report and full report available online through the sample request page and the full report page.

The details: - Pulmozyme is also known as dornase alfa. - Pulmozyme is a recombinant human enzyme, deoxyribonuclease I, or DNase I. - The drug is primarily prescribed for cystic fibrosis patients. - Pulmozyme breaks down DNA in thick lung mucus and lowers mucus viscosity. - The drug is administered through a nebulizer. - Pulmozyme can improve lung function, ease breathing, and help reduce respiratory infections by clearing mucus blockages. - The report identifies increasing genetic screening as a future growth driver because it supports earlier diagnosis. - Rising COPD cases are another expected driver. - The expansion of specialized respiratory care services is expected to support demand. - Better patient compliance, expanded plasma collection capacity, and improved healthcare infrastructure are also listed as growth factors. - The report highlights rising use of augmentation therapy. - The report also points to growing interest in slowing COPD progression. - Long-term plasma protein replacement therapies are becoming more common. - Pulmozyme use in hospitals and specialty clinics is gaining traction. - Increasing awareness of genetic lung disorders is expected to support market development. - The report says the market has grown in prior years because of Pulmozyme’s effectiveness in alpha-1 antitrypsin deficiency, pulmonology guideline support, availability of plasma-derived proteins, and more specialist prescribing. - Improved approaches to respiratory disease management also contributed to earlier market growth. - The global respiratory disease burden remains a major market driver. - The Australian Institute of Health and Welfare estimated in June 2024 that about 8.5 million Australians, or 34% of the population, had chronic respiratory conditions. - That same estimate included about 2.8 million people with asthma and 638,000 people with COPD. - The report links wider respiratory disease prevalence to higher treatment demand for mucus-clearing therapies like Pulmozyme. - Lung transplant growth is another market support factor. - Lung transplants replace a damaged lung with a healthy donor organ to treat severe lung failure or chronic disease. - The report says transplant volume is rising because of more cystic fibrosis and COPD cases, plus medical advances in surgery and post-transplant care. - Pulmozyme is described as important for transplant recipients because it can reduce thick airway mucus and lower infection risk. - UK National Health Service data show active lung and heart-lung transplant patients rising from 267 in 2022 to 302 in 2023.

Between the lines: - The report frames Pulmozyme’s market around both chronic disease prevalence and advanced respiratory care, which suggests demand is being pulled by routine treatment needs and more complex clinical settings. - Regional growth patterns point to a mature North American market and faster expansion potential in Asia-Pacific, where healthcare access and respiratory care capacity may be improving. - The emphasis on genetic screening and early diagnosis suggests future growth may depend as much on detection as on treatment volume.

What's next: - The Business Research Company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, market hotspot infographics, and updated graphics and tables. - The company is also offering direct expert contact for buyers seeking more information on the market outlook.

The bottom line: - Pulmozyme’s market case is being driven by more respiratory disease, more transplant care, and broader use of specialized respiratory therapies, with North America leading now and Asia-Pacific set to accelerate.